187 related articles for article (PubMed ID: 36791582)
1. The PTEN-associated immune prognostic signature reveals the landscape of the tumor microenvironment in glioblastoma.
Yu J; Lai M; Zhou Z; Zhou J; Hu Q; Li J; Li H; Chen L; Wen L; Zhou M; Cai L
J Neuroimmunol; 2023 Mar; 376():578034. PubMed ID: 36791582
[TBL] [Abstract][Full Text] [Related]
2. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
3. Identification of an Immune-Related Prognostic Signature for Glioblastoma by Comprehensive Bioinformatics and Experimental Analyses.
Ye S; Yang B; Zhang T; Wei W; Li Z; Chen J; Li X
Cells; 2022 Sep; 11(19):. PubMed ID: 36230961
[TBL] [Abstract][Full Text] [Related]
4. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
5. A novel Foxp3-related immune prognostic signature for glioblastoma multiforme based on immunogenomic profiling.
Guo XY; Zhang GH; Wang ZN; Duan H; Xie T; Liang L; Cui R; Hu HR; Wu Y; Dong JJ; He ZQ; Mou YG
Aging (Albany NY); 2021 Jan; 13(3):3501-3517. PubMed ID: 33429364
[TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment Characterization in Glioblastoma Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
Zhang J; Xiao X; Zhang X; Hua W
J Mol Neurosci; 2020 May; 70(5):738-750. PubMed ID: 32006162
[TBL] [Abstract][Full Text] [Related]
7. Immune landscape-based machine-learning-assisted subclassification, prognosis, and immunotherapy prediction for glioblastoma.
Li H; He J; Li M; Li K; Pu X; Guo Y
Front Immunol; 2022; 13():1027631. PubMed ID: 36532035
[TBL] [Abstract][Full Text] [Related]
8. Tetraspanins predict the prognosis and characterize the tumor immune microenvironment of glioblastoma.
Li YC; Wu Y; Chen G; Zhu LZ; Luo X; Nie QQ; Zhang L; Zuo CJ
Sci Rep; 2023 Aug; 13(1):13317. PubMed ID: 37587203
[TBL] [Abstract][Full Text] [Related]
9. Integrating machine learning and bioinformatics analysis to m6A regulator-mediated methylation modification models for predicting glioblastoma patients' prognosis and immunotherapy response.
Li C; Liu W; Liu C; Luo Q; Luo K; Wei C; Li X; Qin J; Zheng C; Lan C; Wei S; Tan R; Chen J; Chen Y; Huang H; Zhang G; Huang H; Wang X
Aging (Albany NY); 2023 May; 15(10):4051-4070. PubMed ID: 37244287
[TBL] [Abstract][Full Text] [Related]
10. Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.
Ding MR; Qu YJ; Peng X; Chen JF; Zhang MX; Zhang T; Hu B; An HM
BMC Cancer; 2022 Jun; 22(1):611. PubMed ID: 35658846
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.
Sun Z; Zhao Y; Wei Y; Ding X; Tan C; Wang C
Front Immunol; 2022; 13():939523. PubMed ID: 36091049
[TBL] [Abstract][Full Text] [Related]
12. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.
Ji H; Ba Y; Ma S; Hou K; Mi S; Gao X; Jin J; Gong Q; Liu T; Wang F; Liu Z; Li S; Du J; Hu S
Front Immunol; 2021; 12():729359. PubMed ID: 34566988
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Different Subtypes of Immune Cell Infiltration in Glioblastoma to Aid Immunotherapy.
Feng P; Li Z; Li Y; Zhang Y; Miao X
Front Immunol; 2022; 13():799509. PubMed ID: 35799789
[TBL] [Abstract][Full Text] [Related]
14. Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma.
Zhao L; Zhang J; Xuan S; Liu Z; Wang Y; Zhao P
Front Cell Dev Biol; 2021; 9():600506. PubMed ID: 33614641
[No Abstract] [Full Text] [Related]
15. Identification of Immune Cell Infiltration and Immune-Related Genes in the Tumor Microenvironment of Glioblastomas.
Huang S; Song Z; Zhang T; He X; Huang K; Zhang Q; Shen J; Pan J
Front Immunol; 2020; 11():585034. PubMed ID: 33193404
[TBL] [Abstract][Full Text] [Related]
16. Interaction, immune infiltration characteristics and prognostic modeling of efferocytosis-related subtypes in glioblastoma.
Zhao S; Wang Q; Liu Y; Zhang P; Ji W; Xie J; Cheng C
BMC Med Genomics; 2023 Oct; 16(1):248. PubMed ID: 37853449
[TBL] [Abstract][Full Text] [Related]
17. The N
Zhao R; Li B; Zhang S; He Z; Pan Z; Guo Q; Qiu W; Qi Y; Zhao S; Wang S; Chen Z; Zhang P; Guo X; Xue H; Li G
Front Immunol; 2021; 12():653711. PubMed ID: 34354698
[TBL] [Abstract][Full Text] [Related]
18. The immune cell landscape of glioblastoma patients highlights a myeloid-enriched and immune suppressed microenvironment compared to metastatic brain tumors.
Musca B; Russo MG; Tushe A; Magri S; Battaggia G; Pinton L; Bonaudo C; Della Puppa A; Mandruzzato S
Front Immunol; 2023; 14():1236824. PubMed ID: 37936683
[TBL] [Abstract][Full Text] [Related]
19. Combining single-cell sequencing and spatial transcriptome sequencing to identify exosome-related features of glioblastoma and constructing a prognostic model to identify BARD1 as a potential therapeutic target for GBM patients.
Zhao S; Wang Q; Ni K; Zhang P; Liu Y; Xie J; Ji W; Cheng C; Zhou Q
Front Immunol; 2023; 14():1263329. PubMed ID: 37727789
[TBL] [Abstract][Full Text] [Related]
20. Identification, validation and biological characterisation of novel glioblastoma tumour microenvironment subtypes: implications for precision immunotherapy.
White K; Connor K; Meylan M; Bougoüin A; Salvucci M; Bielle F; O'Farrell AC; Sweeney K; Weng L; Bergers G; Dicker P; Ashley DM; Lipp ES; Low JT; Zhao J; Wen P; Prins R; Verreault M; Idbaih A; Biswas A; Prehn JHM; Lambrechts D; Arijs I; Lodi F; Dilcan G; Lamfers M; Leenstra S; Fabro F; Ntafoulis I; Kros JM; Cryan J; Brett F; Quissac E; Beausang A; MacNally S; O'Halloran P; Clerkin J; Bacon O; Kremer A; Chi Yen RT; Varn FS; Verhaak RGW; Sautès-Fridman C; Fridman WH; Byrne AT
Ann Oncol; 2023 Mar; 34(3):300-314. PubMed ID: 36494005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
